CPX-101

重组人胰高糖素样肽1修饰抗人葡萄糖依赖性促胰岛素释放肽受体的人源化单克隆抗体 (正大制药)

Report date: 2026/05/20 20:02:01

Base Information

Drug NameCPX-101
Drug Alias NameCPX101CPX-101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionGlucose-Dependent Insulinotropic Polypeptide Receptor antagonistsGlucagon-like peptide 1 receptor agonists
TargetsGlucose-Dependent Insulinotropic Polypeptide ReceptorGlucagon-like peptide 1 receptor
Therapy Area/IndicationsOverweightObesity
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGuangzhou Chia Tai Innovative Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGuangzhou Chia Tai Innovative Pharmaceutical Co LtdChia Tai Pharmaceutical (Guangzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsOverweightObesity
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A